Rare Disease Diagnostics.
Onsight, Wherever You Are.
In Vitro Diagnostic Solutions (IVDS): Building a point-of-care ecosystem for rare metabolic and related diseases.
Built for a New Era of Rare Disease Diagnostics
From distant labs and delayed reports to near-patient, app-connected insight.
IVDS was founded to offer simple-to-use point-of-care diagnostics for rare metabolic and related diseases. With the Onsight platform, patients and clinicians can see key biomarker data in minutes instead of waiting days for external lab results, whether testing in a clinic, NICU, specialty center, or at home.
Why Choose IVDS Onsight?
From a Single Drop to Actionable Insight
Onsight uses a small capillary blood sample, reflectance-based measurement, and a mobile app interface to quantify analytes of interest and display numeric results with units, reference information, and trends over time.
Designed for Clinics, Homes & Telehealth
Metabolic clinics, NICUs, specialty centers, and families can use Onsight-generated results to support real-time decisions in visits, regular monitoring at home, and testing just before or during video appointments.
A Flexible Platform & Growing Evidence Base
One meter and app can support multiple analytes through disease-specific strips and algorithms, informed by ongoing studies and collaborations with hospitals, labs, NGOs, pharma, and rare disease communities.
“Onsight helps us see analyte levels in minutes instead of waiting on external lab reports, so we can adjust diet, medications, and monitoring schedules based on current data.”
— Clinician using IVDS Onsight in a metabolic clinic setting
What We Offer
A growing menu of Onsight-enabled tests for rare metabolic and related conditions.
PKU Now
A home and point-of-care platform in development to quantify blood phenylalanine (Phe) for people living with phenylketonuria (PKU). PKU Now provides the test, smart workflows, data visualization, and a connected web dashboard for clinicians.
PreQuine – G6PD deficiency
PreQuine is a point-of-care platform for simultaneous, quantitative measurement of G6PD enzyme activity and hemoglobin in a single small blood sample, designed to support safer use of oxidant drugs in malaria and related settings.
ADA2 Now – ADA2 deficiency (DADA2)
ADA2 Now is being developed as a rapid, point-of-care blood test to quantify ADA2 enzyme levels to support diagnosis and monitoring of DADA2.
CPK Now, HCY Now, Bili Now & Hb Now
CPK Now is intended to measure creatine phosphokinase (CPK) at the point of care, HCY Now is a planned assay for homocysteine, Bili Now targets bilirubin testing in neonatal settings, and Hb Now is conceived as an affordable, portable hemoglobin test connected to a mobile app for secure result tracking.
Pipeline and regulatory note: Assays are at different stages of research, validation, and regulatory review. Products described here are investigational and not yet cleared or approved for routine clinical use; availability will vary by region and over time.
We Don’t Just Measure — We Partner
Rare metabolic and related conditions touch clinicians, families, and health systems in different ways but all depend on timely, reliable data. The Onsight ecosystem is designed to serve each stakeholder, extending rare disease expertise beyond the walls of the clinic and into patients’ homes through close collaboration with patient communities, foundations, and institutional partners.
Perspectives
How Stakeholders Use Onsight
Explore how clinicians, families, and partners engage with the platform.
Clinicians, Clinics & Hospitals
Metabolic specialists, pediatricians, nurses, and dietitians can use Onsight-generated results to see analyte levels in minutes, adjust diet, medications, and monitoring schedules based on current data, and integrate point-of-care and home testing into existing clinic and telehealth workflows.
— Metabolic specialist, university hospital
Patients & Families
For individuals living with PKU, G6PD deficiency, ADA2 deficiency, fatty acid oxidation disorders, and other conditions, the Onsight ecosystem aims to provide clearer, more frequent feedback with small-sample tests, reduce the burden of repeated hospital visits and mailed samples, and make complex lab values easier to understand through app-based visualization and education.
— Parent of a child with a rare metabolic condition
Partners & Global Programs
Hospitals and labs, pharmaceutical and biotech companies, NGOs, and global health organizations can collaborate with IVDS to deploy point-of-care and at-home tests, develop companion diagnostics and longitudinal monitoring tools, and extend access in malaria- and anemia-endemic regions where G6PD and hemoglobin testing are critical.
— Program lead, global health initiative